Gianpiero Romano

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Skin lesions in diabetes mellitus: prevalence and clinical correlations

Gianpiero Romano, Giovanna Moretti, A Di Benedetto et al. · Diabetes Research and Clinical Practice · 1998 · 179 citations

Diabetes, Skin Lesions, Clinical Dermatology +3

Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers.

Alessandro Sgambato, Mario Migaldi, Beatrice Faraglia et al. · PubMed · 1999 · 79 citations

Reduced Disease-free Survival, Pathology, Cancer Biology +17

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 78 citations · Full text

Nivolumab Versus Docetaxel, Medicine, Pharmacology +7

Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in human colon cancer

Alessandro Sgambato, Carlo Ratto, Beatrice Faraglia et al. · Molecular Carcinogenesis · 1999 · 67 citations